Abstract
Background: A secondary analysis of pooled data, stratified by concomitant inhaled corticosteroid (ICS) use, is presented from ACLIFORM (NCT01462942) and AUGMENT (NCT01437397), two Phase III, 24-week, randomised, double-blind studies of twice-daily (BID) aclidinium/formoterol (AB/FF) fixed-dose combination in patients (pts) with moderate to severe airflow obstruction.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
